BeiGene, Ltd. Price & Performance (ONC)

Several major financial institutions have recently raised their 12-month price targets for BeiGene, with consensus now averaging above $316 per share. This comes as the company continues to post robust revenue growth and maintain a strong product pipeline, despite a recent trial discontinuation. Investor sentiment remains largely positive.123

BeiGene is set to announce its first quarter 2025 financial results on May 7. The company, which is also planning a rebrand to BeOne Medicines, will host a webcast to discuss its performance and outlook. Investors are watching closely for updates on drug sales and pipeline progress.45

BeiGene's stock has experienced notable price swings recently, with a 4.4% decline over the past week but a year-to-date rise exceeding 32%. Trading volumes remain robust, reflecting continued investor interest as the company navigates both clinical successes and setbacks in its oncology portfolio.678